Cancer's New Future: From Death Sentence to Chronic Condition

The Question

There is a type of blood cancer called chronic myeloid leukaemia — CML for short. In the 1990s, a diagnosis meant you had roughly five years to live. Then, in 2001, a targeted drug called imatinib arrived. Today, more than 90% of CML patients are alive ten years after diagnosis. The cancer didn't disappear. It became something people live with, not die from.

Our model gives this 68% probability. The science is converging from four directions: immune cell therapies that use your own body to hunt cancer; personalised vaccines trained against your specific tumour; AI that catches cancer early enough to cure it; and blood tests that find tumour DNA in your bloodstream before symptoms appear. The CML story is the proof of concept. The question is how fast, and for which cancers, it can be repeated.

What the Evidence Shows

The trend lines are real. Overall five-year cancer survival rates in the US have risen from 49% in 1975 to 69% today, according to the American Cancer Society. Cancer death rates have fallen by 33% since 1991 — driven by less smoking, better screening, and improved treatment. Those numbers hide enormous variation between cancer types and patients, but the direction has been clear for decades.

The most dramatic new tool is CAR-T therapy. Doctors take your immune cells, reprogram them in a lab to recognise and attack your cancer, then infuse them back. For blood cancers and lymphomas, it has achieved complete remission in patients who had failed every other treatment — patients who, not long ago, would have had weeks. Meanwhile, BioNTech — the company behind the first mRNA COVID vaccine — is in late-stage trials with a personalised mRNA cancer vaccine that targets mutations unique to each patient's tumour. Early melanoma results are beating expectations.

Detection is being transformed too. A blood test called Galleri, developed by GRAIL, can detect signs of more than 50 cancer types from a single blood draw — including cancers with no standard screening test today — by finding tumour DNA in the bloodstream before symptoms appear. AI is also now reading mammograms, CT scans, and pathology slides with accuracy that matches or beats experienced radiologists. Catching cancer earlier, when it's still confined and curable, is arguably the single most powerful lever medicine has.

Why This Is Happening

The cost of these treatments is its own crisis. A single course of CAR-T therapy costs $400,000 to $500,000. Personalised mRNA vaccines, once approved, are unlikely to be priced below six figures. Even in countries with public healthcare, cancer treatment costs are straining budgets. In the US, tens of thousands of families face financial ruin from treatment bills every year. The scientific revolution and the access failure could coexist entirely — better outcomes for the wealthy, unchanged mortality for everyone else.

Racial gaps in cancer outcomes are wide and stubbornly persistent. Black Americans have a 20% higher cancer death rate than white Americans — the result of later diagnoses, lower access to screening, and unequal access to the newest treatments. Hispanic and Indigenous communities face similar barriers. Any serious claim that cancer is being "transformed" needs to grapple with these inequities. Better drugs improve the national average while leaving the most disadvantaged unchanged, unless access is deliberately addressed.

Not everyone responds to immunotherapy — and we don't yet know why. Treatments that unleash the immune system against cancer work spectacularly in some patients and do almost nothing in others. Working out who will respond before treatment starts — rather than after a futile, expensive, and toxic course — is one of oncology's most urgent unsolved problems.

What Could Happen

What Can We Do

Prevention is where the real leverage is — and it's the most consistently underrated tool in cancer. Around 40 to 45% of cancer cases in wealthy countries are linked to things people can actually change: smoking, heavy drinking, obesity, physical inactivity, and certain infections. Anti-smoking campaigns have already done more to cut cancer deaths than any drug ever has. The next big frontier is obesity — the second leading preventable cause of cancer after tobacco. Weight-loss drugs like semaglutide (Ozempic) could have a significant impact on cancer incidence over the coming decade, simply by addressing one of its biggest drivers.

For you personally, the highest-return action is straightforward: get screened. Mammograms, colonoscopies, low-dose CT scans for heavy smokers, and cervical smear tests are all associated with real mortality reductions. The HPV vaccine — which most people associate with cervical cancer — also prevents cancers of the throat, anus, and penis, and coverage remains below optimal in most countries. If you or someone you know has put off a routine screening, now is the time. The treatments coming down the pipeline are most effective when the cancer is caught early. Screening is how you get there.

At the policy level, the most impactful changes would be requiring all insurers to cover participation in cancer clinical trials, increasing prevention funding relative to treatment, and negotiating international drug pricing so life-saving therapies reach lower-income countries at differential cost. The science is winning. The delivery system needs to catch up.